DE69736290D1 - Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens-oligonukleotide die an grb2 zielgerichtet sind - Google Patents

Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens-oligonukleotide die an grb2 zielgerichtet sind

Info

Publication number
DE69736290D1
DE69736290D1 DE69736290T DE69736290T DE69736290D1 DE 69736290 D1 DE69736290 D1 DE 69736290D1 DE 69736290 T DE69736290 T DE 69736290T DE 69736290 T DE69736290 T DE 69736290T DE 69736290 D1 DE69736290 D1 DE 69736290D1
Authority
DE
Germany
Prior art keywords
grb2
targeted
inhibition
growth
leukemic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736290T
Other languages
English (en)
Other versions
DE69736290T2 (de
Inventor
Gabriel Lopez-Berestein
Ana M Tari
B Arlinghaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of DE69736290D1 publication Critical patent/DE69736290D1/de
Application granted granted Critical
Publication of DE69736290T2 publication Critical patent/DE69736290T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69736290T 1996-07-08 1997-07-08 Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens-oligonukleotide die an grb2 zielgerichtet sind Expired - Lifetime DE69736290T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/679,437 US7309692B1 (en) 1996-07-08 1996-07-08 Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US679437 1996-07-08
PCT/US1997/010101 WO1998001547A1 (en) 1996-07-08 1997-07-08 INHIBITION OF CHRONIC MYELOGENOUS LEUKEMIC CELL GROWTH BY LIPOSOMAL-ANTISENSE OLIGODEOXY-NUCLEOTIDES TARGETING TO Grb2 OR Crk1

Publications (2)

Publication Number Publication Date
DE69736290D1 true DE69736290D1 (de) 2006-08-17
DE69736290T2 DE69736290T2 (de) 2007-07-05

Family

ID=24726909

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69738459T Expired - Lifetime DE69738459T2 (de) 1996-07-08 1997-07-08 Hemmung des Wachstums der chronischen Myelogenen leukämischen Zellen durch antisens-Oligonukleotide die an Crkl zielgerichtet sind
DE69736290T Expired - Lifetime DE69736290T2 (de) 1996-07-08 1997-07-08 Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens-oligonukleotide die an grb2 zielgerichtet sind

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69738459T Expired - Lifetime DE69738459T2 (de) 1996-07-08 1997-07-08 Hemmung des Wachstums der chronischen Myelogenen leukämischen Zellen durch antisens-Oligonukleotide die an Crkl zielgerichtet sind

Country Status (9)

Country Link
US (3) US7309692B1 (de)
EP (2) EP1234876B1 (de)
JP (1) JP2000514438A (de)
AT (2) ATE383422T1 (de)
AU (1) AU740289B2 (de)
CA (2) CA2741501A1 (de)
DE (2) DE69738459T2 (de)
ES (2) ES2299536T3 (de)
WO (1) WO1998001547A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062911A2 (en) * 2000-02-24 2001-08-30 Ribozyme Pharmaceuticals, Inc. Antisense and catalytically acting nucleic acid molecules targeted to grb2- related with insert domain (grid) proteins and their uses
EP1874793A4 (de) 2005-04-15 2008-12-24 Univ Texas Abgabe von sirna durch neutrale lipid-zusammensetzungen
US8900627B2 (en) * 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
US20110189095A1 (en) * 2008-06-20 2011-08-04 The Board Of Regents, Of The University Of Texas System Crkl targeting peptides
SG10202104058XA (en) 2015-10-14 2021-05-28 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
ES2928654T3 (es) 2016-09-16 2022-11-21 Bio Path Holdings Inc Terapia combinada con oligonucleótidos antisentido liposomales
US11041153B2 (en) 2017-04-19 2021-06-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for STAT3 inhibition

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (de) 1977-08-05 1981-02-13 Battelle Memorial Institute
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5094785A (en) 1986-12-10 1992-03-10 Ciba Corning Diagnostics Corp. Process for stabilizing liposomes
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5225326A (en) * 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
ATE120640T1 (de) 1989-04-18 1995-04-15 Vestar Inc Markierung mit liposomen von ischämischen geweben.
CA2033725C (en) 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
EP0464638B1 (de) 1990-07-02 1997-04-02 Hoechst Aktiengesellschaft Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
JPH06508622A (ja) * 1991-06-18 1994-09-29 テンプル　ユニバーシティ−オブ　ザ　コモンウェルス　システム　オブ　ハイヤーエデュケーション ｂｃｒ−ａｂ１アンチセンスオリゴヌクレオチドによる白血球増殖の選択的抑制
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
FR2710074B1 (fr) 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
JPH09505465A (ja) 1993-09-28 1997-06-03 ザ ジェネラル ホスピタル コーポレイション 神経増殖を調整し、β／Ａ４アミロイド誘発形態を逆転させる為のアンチセンスオリゴヌクレオチドの使用
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
CA2113494A1 (en) 1994-01-14 1995-07-15 Lorri Puil Method for assaying for substances which affect bcr-abl mediated transformation
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5667981A (en) 1994-05-13 1997-09-16 Childrens Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
US5696248A (en) 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
ATE332710T1 (de) 1995-06-01 2006-08-15 Kishimoto Tadamitsu Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms- tumorgen enthält
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
IL122290A0 (en) 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
HUP9802445A3 (en) 1995-08-01 1999-03-29 Novartis Ag Liposomal oligonucleotide compositions and process for inhibiting the human raf
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
AU4510396A (en) 1995-12-04 1997-06-27 Human Genome Sciences, Inc. Growth factor receptor-binding protein 2 homolog
US5874224A (en) 1997-03-11 1999-02-23 Incyte Pharmaceuticals, Inc. Growth factor receptor binding protein
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
GB9711919D0 (en) 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
TWI225412B (en) 1997-06-23 2004-12-21 Sequus Pharm Inc Liposome-entrapped polynucleotide composition and method
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US6136965A (en) 1998-07-02 2000-10-24 The Regents Of The University Of California Deoxynucleic alkyl and alkoxy thiourea compounds
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6323487B1 (en) * 1999-01-26 2001-11-27 Delphi Technologies, Inc. IR optical position sensor system
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Also Published As

Publication number Publication date
US7309692B1 (en) 2007-12-18
US20030153526A1 (en) 2003-08-14
EP0912729A1 (de) 1999-05-06
CA2259144A1 (en) 1998-01-15
DE69738459D1 (de) 2008-02-21
AU740289B2 (en) 2001-11-01
EP1234876B1 (de) 2008-01-09
US7923548B2 (en) 2011-04-12
AU3569497A (en) 1998-02-02
JP2000514438A (ja) 2000-10-31
ATE332369T1 (de) 2006-07-15
EP1234876A1 (de) 2002-08-28
ES2299536T3 (es) 2008-06-01
DE69738459T2 (de) 2008-12-24
US20070238686A1 (en) 2007-10-11
WO1998001547A1 (en) 1998-01-15
DE69736290T2 (de) 2007-07-05
ES2268731T3 (es) 2007-03-16
US7220853B2 (en) 2007-05-22
CA2741501A1 (en) 1998-01-15
EP0912729B1 (de) 2006-07-05
ATE383422T1 (de) 2008-01-15
CA2259144C (en) 2011-09-20

Similar Documents

Publication Publication Date Title
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
EP2796554A3 (de) Zusammensetzungen zur Behandlung von BCL2-assoziiertem Krebs
ATE508188T1 (de) Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
ATE221914T1 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
BRPI0418463A (pt) métodos de inibir expressão de stat3 humano, de induzir apoptose em células de carcinoma do pulmão, e de inibir crescimento de tumor de linfoma de células t, tumor alcl, e tumor mieloma múltiplo em um animal
EP1165594A4 (de) Antisens oligonucleotide-modulierung der stat3 expression
ATE416183T1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
DK1178999T3 (da) L-RIBO-LNA-analoger
WO2005047477A3 (en) Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
AU2001290706A1 (en) Antisense modulation of clusterin expression
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
ATE275956T1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
WO2003048315A3 (en) Antisense modulation of mdm2 expression
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
DE69736290D1 (de) Hemmung des wachstums der chronischen myelogenen leukämischen zellen durch antisens-oligonukleotide die an grb2 zielgerichtet sind
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2001060998A3 (en) Small oligonucleotides with anti-tumor activity
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
WO2006066154A3 (en) Casein kinase 2 antisense therapy
EP1248795A4 (de) Antisens-modulierung der expression des makrophagenmigrationshemmenden faktors
DE10346721A1 (de) Oligonukleotide, diese enthaltende Mittel und deren Verwendung
EP1102862A4 (de) Antisense olignukleotide gegen il-15
EP1322658A4 (de) Oligonukleotidmodulation der her-1-expression
WO2021262919A3 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition